TWi Biotechnology, Inc. (TPEX:6610)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
20.60
-1.75 (-7.83%)
Mar 9, 2026, 1:57 PM CST
76.07%
Market Cap 2.22B
Revenue (ttm) n/a
Net Income (ttm) -155.28M
Shares Out 107.63M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 309,182
Average Volume 483,560
Open 22.50
Previous Close 22.35
Day's Range 19.60 - 22.50
52-Week Range 8.96 - 40.85
Beta 0.63
RSI 48.81
Earnings Date Apr 2, 2026

About TWi Biotechnology

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 23
Stock Exchange Taipei Exchange
Ticker Symbol 6610
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.